These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 6953987)

  • 1. Evaluation of AMSA in previously treated patients with acute leukemia: results of therapy in 109 adults.
    Legha SS; Keating MJ; McCredie KB; Bodey GP; Freireich EJ
    Blood; 1982 Aug; 60(2):484-90. PubMed ID: 6953987
    [TBL] [Abstract][Full Text] [Related]  

  • 2. m-AMSA: phase II trial in advanced lymphoma and leukemia.
    Case DC
    Am J Clin Oncol; 1984 Aug; 7(4):357-60. PubMed ID: 6588746
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase I and II study of m-AMSA in acute leukaemia.
    Slevin ML; Shannon MS; Prentice HG; Goldman AJ; Lister TA
    Cancer Chemother Pharmacol; 1981; 6(2):137-40. PubMed ID: 6946878
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Amsacrine in refractory acute leukemia.
    Griffin JD; Maguire ME; Mayer RJ
    Cancer Treat Rep; 1985; 69(7-8):787-9. PubMed ID: 3860296
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 4'-(9-Acridinylamino) methanesulfon-m-anisidide (AMSA): a new drug effective in the treatment of adult acute leukemia.
    Legha SS; Keating MJ; Zander AR; McCredie KB; Bodey GP; Freireich EJ
    Ann Intern Med; 1980 Jul; 93(1):17-21. PubMed ID: 6930826
    [TBL] [Abstract][Full Text] [Related]  

  • 6. AMSA--a promising new agent in refractory acute leukemia.
    Lawrence HJ; Ries CA; Reynolds RD; Lewis JP; Koretz MM; Torti FM
    Cancer Treat Rep; 1982 Jul; 66(7):1475-8. PubMed ID: 7046928
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of acute leukemia in relapse with 4'(9-acridinylamino) methanesulfon-m-anisidide (AMSA) in combination with cytosine arabinoside and thioguanine.
    Arlin ZA; Flomenberg N; Gee TS; Kempin SJ; Dellaquila C; Mertelsmann R; Straus DJ; Young CW; Clarkson BD
    Cancer Clin Trials; 1981; 4(3):317-21. PubMed ID: 6895190
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II study of 4'-(9-acridinylamino)methanesulfon-m-anisidide (NSC 249992) in children with acute leukemia and lymphoma.
    Tan CT; Hancock C; Steinherz PG; Steinherz LJ; Sorell M; Chan KW; Mondora A; Miller DR
    Cancer Res; 1982 Apr; 42(4):1579-81. PubMed ID: 6895864
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 4'-(9-acridinylamino)methane-sulfon-m-anisidide (m-AMSA) and 5-azacytidine (AZA) in the treatment of relapsed adult acute leukemia.
    Kahn SB; Sklaroff R; Lebedda J; Conroy JF; Bulova S; Brodsky I
    Am J Clin Oncol; 1983 Aug; 6(4):493-502. PubMed ID: 6191561
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Combination of AMSA-high dose cytosine arabinoside in acute leukemia].
    Zittoun R; Rio B; Marie JP; Blanc CM
    Presse Med; 1985 Jun; 14(26):1417-20. PubMed ID: 3161047
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of AMSA in children with acute leukemia. A Pediatric Oncology Group study.
    Krischer J; Land VJ; Civin CI; Ragab AH; Mahoney DH; Frankel LS
    Cancer; 1984 Jul; 54(2):207-10. PubMed ID: 6586277
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prediction of complete remission in patients with refractory acute leukemia treated with AMSA.
    Estey EH; Keating MJ; Smith TL; McCredie KB; Legha SS; Walters RS; Bodey GP; Freireich EJ
    J Clin Oncol; 1984 Feb; 2(2):102-6. PubMed ID: 6583328
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sequentially administered 5-azacitidine and amsacrine in refractory adult acute leukemia: a phase I-II trial of the Southeastern Cancer Study Group.
    Winton EF; Hearn EB; Martelo O; Presant CA; Adler S; Vogler WR; Raney M; Logan T; Silberman HM; Omura GA
    Cancer Treat Rep; 1985; 69(7-8):807-11. PubMed ID: 2410119
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical activity of m-Amsa and the combination of m-Amsa with cytosine arabinoside].
    Weil M; Auclerc MF; Schaison G; Auclerc G; Daubrisson A; Degos L; Caro J; Marty M; Jacquillat GI
    Nouv Presse Med; 1982 Oct; 11(39):2911-4. PubMed ID: 6755389
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of refractory adult lymphoblastic leukemia (ALL) with 4'(9-acridinylamino) methanesulfon-M-anisidide (AMSA).
    Arlin ZA; Fanucchi MP; Gee TS; Kempin SJ; Mertelsmann R; Young CW; Clarkson BD
    Blood; 1982 Nov; 60(5):1224-6. PubMed ID: 6957250
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Amsacrine (AMSA).
    Issell BF
    Cancer Treat Rev; 1980 Jun; 7(2):73-83. PubMed ID: 6931632
    [No Abstract]   [Full Text] [Related]  

  • 17. Trial of AMSA in acute leukemia.
    Dupont JC; Garay GE; Scaghone C; Pavlovsky S; Woodley PV
    Cancer Treat Rep; 1982 Jul; 66(7):1596-7. PubMed ID: 7046933
    [No Abstract]   [Full Text] [Related]  

  • 18. High-dose amsacrine (AMSA) therapy of relapsed and refractory adult acute nonlymphocytic leukemia. A phase II study.
    Cassileth PA; Lyman GH; Bennett JM; Glick JH; Oken MM
    Am J Clin Oncol; 1984 Aug; 7(4):361-3. PubMed ID: 6547566
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II study of amsacrine gluconate in refractory leukemia.
    Omura GA; Winton EF; Vogler WR; Zuckerman KS; Grillo-Lopez AJ
    Cancer Treat Rep; 1983 Dec; 67(12):1131-2. PubMed ID: 6580948
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Amsacrine (m-AMSA): a new antineoplastic agent. Pharmacology, clinical activity and toxicity.
    Hornedo J; Van Echo DA
    Pharmacotherapy; 1985; 5(2):78-90. PubMed ID: 2582401
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.